Absci rises on collaboration with AMD and Oracle for AI drug discovery

** Shares of AI-based drug developer Absci ABSI.O rise 5.5% to $2.51 premarket

** Co announces collaboration with Oracle Cloud Infrastructure ORCL.N and Advanced Micro Devices AMD.O to accelerate generative AI-driven drug discovery

** Co's drug discovery platform uses Oracle's AI infrastructure and AMD's latest hardware - ABSI

 ** Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future

** ABSI in January said AMD will invest $20 mln in co to power AI drug discovery

** Up to last close, ABSI down 9.2% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Recent news on AbSci

See all news